Document Type
Article
Publication Date
6-2022
Abstract
The TMPRSS2-ERG fusion gene has frequently been found in prostate cancer and is associated with malignancy. Identifying novel fusions will help to stratify patients and establish patient-tailored therapies. A 78-year-old man presented to our hospital with severe symptoms of urinary urgency and frequency for 2 years, as well as severe bone pain for 1 year. He was diagnosed with metastatic prostate cancer with a Gleason score of 5 + 5. Three gene fusions, ERG_VEGFA, TMPRSS2_ERG, and VEGFA_TMPRSS2, were identified in the patient's prostate cancer tissue. Notably, administration of the tyrosine kinase inhibitor, anlotinib, in combination with a gonadotropin-releasing hormone agonist (GnRHa) and abiraterone, reduced the patient's bone pain and also stabilized his prostate cancer for more than 2 years. This is the first report of somatic fusions among the VEGFA, ERG, and TMPRSS2 genes in cancer tissues from a patient with prostate cancer who responded well to antiangiogenic treatment combined with a GnRHa and abiraterone.
Publication Title
Cancer Innovation
Volume
1
Issue
1
First Page
114
Last Page
118
Recommended Citation
Liu, Qiuli; Wang, Shuo; Wang, Ze; Tang, Peng; Zhang, Dianzheng; Lan, Weihua; and Jiang, Jun, "Identification of novel somatic fusions of ERG-VEGFA, TMPRSS2-ERG, and VEGFA-TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report" (2022). PCOM Scholarly Papers. 2221.
https://digitalcommons.pcom.edu/scholarly_papers/2221
Comments
This article was published in Cancer Innovation, Volume 1, Issue 1, pages 114-118.
The published version is available at https://doi.org/10.1002/cai2.11.
Copyright © 2023 The Authors. CC BY-NC-ND 4.0.